Ironwood Pharmaceuticals (IRWD) Other Accumulated Expenses (2010 - 2026)

Ironwood Pharmaceuticals has reported Other Accumulated Expenses for 17 years, with the latest figure at $6.0 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 20.84% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 20.84% YoY) and the FY2025 annual result came in at $9.4 million, up 112.92% from the prior year.
• Other Accumulated Expenses retreated to $6.0 million in Q1 2026 per IRWD's latest filing, from $9.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $14.3 million in Q3 2023 and troughed at $3.6 million in Q4 2022.
• A 5-year average of $7.1 million and a median of $6.8 million in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 257.5% in 2023, then tumbled 45.45% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $3.6 million in 2022, then soared by 72.71% to $6.2 million in 2023, then declined by 28.71% to $4.4 million in 2024, then surged by 112.92% to $9.4 million in 2025, then slumped by 36.48% to $6.0 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $6.0 million, $9.4 million, and $6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.